Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 25,190 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PRE Clear all

Conditions: Gaucher Disease, Type 1, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease, Gaucher Disease, Non-Neuronopathic Form
Interventions: Eliglustat tartrate; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 2
States / cities: New York, New York

Conditions: Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms
Interventions: [F-18]-5-FLUORO-2'-DEOXYCYTIDINE, Tetrahydrouridine intravenous (IV), Tetrahydrouridine (oral), Positron emission tomography (PET)/Computed tomography (CT); Drug · Diagnostic Test
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Spasticity With Multiple Sclerosis
Interventions: Nabiximols, Placebo; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: Denver, Colorado • Naples, Florida • Tampa, Florida + 3 more

Conditions: Heavy Drinking, Alcohol Dependence, Alcohol Use Disorder
Interventions: Oral naltrexone (PO-NTX), Extended-release injectable naltrexone (XR-NTX); Drug
Lead sponsor: Boston University; Other
Eligibility: 18 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Wounds, Biofilm Infection, Trans-epidermal Water Loss (TEWL), Diabetic Foot, Diabetic Foot Infection
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Tucson, Arizona • Cranberry Township, Pennsylvania

Conditions: Non-small Cell Lung Cancer
Interventions: MGY825; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 7
States / cities: Boston, Massachusetts • St Louis, Missouri • New York, New York + 1 more

Conditions: Cardiovascular Disease
Interventions: ALT-711 (alagebrium chloride); Drug
Lead sponsor: Synvista Therapeutics, Inc; Industry
Eligibility: 50 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Obesity
Interventions: Control - Inhibition, Experimental I- Inhibition, Experimental II- Inhibition, Control- Stimulation, Experimental I- Stimulation, Experimental II- Stimulation, Sensory Evaluation; Other
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 21 Years to 40 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Champaign, Illinois

Conditions: Evoked Potentials, Visual
Interventions: SightSaver Visual Stimulator; Device
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Pancreatic Cancer, Periampullary Adenocarcinoma
Interventions: Stereotactic Body Radiation Therapy (SBRT); Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Sleep
Interventions: transcranial Direct Current Stimulation (tDCS); Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Functional Deficits, Manipulation, Rehabilitation
Interventions: High Velocity Low Amplitude mobilization, Exercise Protocol; Other
Lead sponsor: Shenandoah University; Other
Eligibility: 16 Years to 35 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Winchester, Virginia

Conditions: Respiration
Interventions: Optical breath-hold control system (OBC); Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Neoplasms
Interventions: Regorafenib (Stivarga, BAY73-4506), Cetuximab (ERBITUX); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 4
States / cities: Los Angeles, California • Aurora, Colorado • St Louis, Missouri + 1 more

Conditions: Hematologic Malignancy
Interventions: Expressive Writing Workshop; Behavioral
Lead sponsor: Blood Cancer United; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Carcinoma, Triple-Negative Breast Carcinoma
Interventions: Biopsy of Breast, Biospecimen Collection, Breast Surgery, Chemotherapy, Computed Tomography, Contrast Enhanced Digital Mammography, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Survey Administration, Tissue Collection, Ultrasound Imaging; Procedure · Drug · Radiation + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Urothelial Carcinoma, Bladder Cancer
Interventions: Abiraterone acetate, Durvalumab, Methotrexate, Vinblastine, Doxorubicin Hydrochloride, Cisplatin; Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 2
States / cities: Bloomington, Indiana • Houston, Texas

Conditions: Overactive Bladder
Interventions: Retrospective chart review; Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Orange, California

Conditions: REM Sleep Behavior Disorder, Pre-motor Parkinson's Disease, Symptomatic Parkinson Disease
Interventions: Terazosin; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 50 Years to 85 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pain
Interventions: Macromastia; Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Frailty, Functional Recovery, Prehabilitation
Interventions: Exercise, Nutrition, Meditation, Cognitive Behavioral Intervention; Behavioral
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 65 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Endothelial Dysfunction
Interventions: Creatine Monohydrate, Maltodextrin (Placebo); Other
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Aortic Valve Disease
Interventions: CAVAREC Image Processing algorithm; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Rheumatoid Arthritis
Interventions: Etanercept; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients

Imaging Study for FdCyd and THU Cancer Treatment

Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis

Alcohol Disorder hOsPital Treatment Trial

Diabetic Foot Ulcer (DFU) Biofilm Infection and Recurrence

Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer

The STRETCH Study: Distensibility on Endothelial-Dependent Vasoreactivity in Subjects With Systolic Hypertension

Role of Sweetness in Glucose Regulation

A Novel Method for Capturing the Visual Evoked Potential During Spine Surgery Under Total Intravenous Anesthesia

Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma

The Effect of Pre-Frontal tDCS on Sleep Propensity During an Afternoon Nap: RCT

Effects of Mobilization in Conjunction With Therapeutic Exercise in Participants With a History of Ankle Sprain

Optical Breath-hold Control System for Image-guided Procedures

Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination

Expressive Writing Program Among Young Adults With Blood Cancer

Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

Combined Anticholinergic Medication and Sacral Neuromodulation to Treat Refractory Overactive Bladder

Terazosin Effect on Cardiac Changes in Early Parkinson's Disease

Enhanced Recovery After Bilateral Reduction Mammaplasty

Multi-Component Prehabilitation for Major Elective Surgery

The Effect of NADPH Oxidase and Creatine Supplementation on Microvascular Blood Flow Regulation

Cardiac Vascular Reconstruction DynaCT for TAVI Procedures

Human Tumor Necrosis Factor Alpha (TNFa)-Induced Pre-B Cell Bone Marrow Emigrants